查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363062

美国口服固态药物合约製造市场规模、份额和趋势分析报告：2023-2030 年按产品类型、机制、最终用途和细分市场分類的趋势

U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, Immediate-release), By End-user, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

美国口服固态药物合约製造市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，预计2023年至2030年美国口服固态药物合约製造市场将以6.1%的年复合成长率成长，到2030年将达到164.2亿美元。

市场的成长得益于国内医药外包增加和技术进步等要素。随着时间的推移，对以患者为中心的剂型的需求不断增加，并已成为医疗领域的重要趋势，因为它提高了用药依从性。因此，製造商生产的口服剂型优先考虑易于吞嚥。

为了使固态口服药物更方便使用，药物赞助商正在创新地将药物转变为微片、迷你片和喷洒胶囊。这种配方方法越来越受欢迎，尤其是在儿童和老年人中。慢性病和感染疾病的日益普及也是推动新疗法需求的主要要素之一。此外，不断增长的老年人口导致慢性病罹患率上升，进一步推动了对新型治疗方法的需求。

现有药物的副作用也增加了对新治疗方法的需求。例如，利物浦大学在 2022 年 7 月发表的一项研究发现，与副作用相关的住院率从 2004 年的 6.5% 增加到 2019 年的 16.5%。现有治疗方法产生副作用的病例数量不断增加，预计将推动未来对新治疗方法的需求。

对许多生物製药公司来说，创新和临床速度是关键因素。小型公司和专业生物製药公司越来越依赖满足其行业内的这些关键要求。许多 CRO 和 CDMO 都标榜自己是一站式服务公司。一站式服务模式意味着CRO负责处理从原料药到剂型、早期开发到商业化的所有事务。为了提供此类服务，CDMO 需要拥有广泛的实行技术和专门的回应能力来解决特定问题。

此外，主要企业加大策略措施的配合措施预计也将促进美国口服固体製剂（OSD）合约製造市场的成长。例如，2023年1月，Catalent和Ethicann合作使用Catalent的口溶锭（ODT）技术Zydis开发Ethicann的临床药物管道。另一个例子，2023 年 3 月，Lonza 宣布其 Visp 工厂的一条新的临床和商业药品生产线全面运作。此次扩张预计将加强该公司的製药服务（DPS）。

美国口服固态製剂合约製造市场报告亮点

  • 依产品类型划分，锭剂部门在 2022 年占据最高市场占有率。这是由于锭剂的普及、易于製造以及患者的高接受度。
  • 预计未来几年胶囊市场将出现显着成长。将多种药理成分配製到具有不同释放特性的胶囊中的可能性推动了他们的需求。
  • 从机制来看，控制释放型在2022年占据市场主导地位。控制释放机制具有多种益处，包括提高功效和安全性、减少给药频率和稳定的血液浓度。
  • 从最终用途来看，大型企业细分市场将在 2022 年占据主导地位。合约製造商通常有能力根据不断变化的需求增加或减少产量。这种弹性对于 OSD 产品需求波动的大型製药企业来说是有利的。
  • 未来年度，中小企业（SME）预计将以显着的速度成长。中小企业的财务资源往往有限。建造和运作自家公司的製造工厂可能太昂贵。透过合约製造，您无需大量初始投资即可获得最先进的生产能力。

目录

第1章调查方法和范围

第2章执行摘要

第3章美国口服固态製剂合约製造市场：变数、趋势、范围

  • 市场体系预测
  • 美国口服固体製剂合约製造动态
  • 市场动态
  • 美国口服固态药物合约製造市场：分析工具
  • 新型冠状病毒感染疾病（COVID-19）的影响
  • 美国以吸塑包装和瓶装分类的口服固体製剂製剂包装类型分析（销售百分比，2022 年）
  • 法规状况

第4章美国口服固态合约製造市场：产品类型分析

  • 美国口服固态製剂合约製造市场按产品类型细分：要点
  • 美国口服固态药物合约製造市场：产品类型变化分析
  • 依产品类型

第5章美国口服固态药物合约製造市场：机制分析

  • 美国口服固态製剂合约製造市场的细分市场机制：要点
  • 美国口服固态药物合约製造市场：机制波动分析
  • 按机理

第6章美国口服固态製剂合约製造市场：最终用户分析

  • 美国口服固态製剂合约製造市场（按最终用户细分）：要点
  • 美国口服固态药物合约製造市场：最终用户波动分析
  • 按最终用途

第7章估计与趋势分析

  • 美国
    • 主要国家趋势
    • 竞争场景

第8章竞争形势

  • 公司分类
  • 服务热图分析
  • 2022年美国口服固态药物合约生产企业市场占有率分析
  • 公司简介
    • Catalent, Inc.
    • Lonza
    • AbbVie Inc.
    • Aenova Group
    • Adare Pharma Solutions
    • Boehringer Ingelheim International GmbH
    • Jubilant Pharmova Limited
    • Patheon Pharma Services
    • Recipharm AB.
    • Corden Pharma International
    • Siegfried Holding AG
Product Code: GVR-4-68040-122-8

U.S. Oral Solid Dosage Contract Manufacturing Market Growth & Trends:

The U.S. oral solid dosage contract manufacturing market size is estimated to reach USD 16.42 billion by 2030, expanding at a CAGR of 6.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth of the market is attributed to factors such as the increasing pharmaceutical outsourcing and technological advancements in the country. The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence. Consequently, manufacturers are producing oral dosage forms that prioritize ease of swallowing.

To render solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs into micro or mini tablets and sprinkle capsules. This formulation approach is gaining popularity, especially among the pediatric and geriatric populations. The growing prevalence of chronic and infectious diseases is one of the major factors responsible for the rising demand for novel therapies. Furthermore, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel treatment processes.

Adverse drug reactions to existing drugs are also contributing to the demand for novel treatment options. For instance, in July 2022, research published by the University of Liverpool stated that adverse drug reaction-related hospital admissions increased from 6.5% in 2004 to 16.5% in 2019. A rise in the number of cases involving adverse drug reactions to existing therapies is expected to boost the demand for new therapies in the future.

For many biopharmaceutical companies, innovations and speed-to-clinic factors are of critical importance. Small companies and specialty biopharmaceutical players increasingly rely upon delivering these important requirements within the industry. Many CROs and CDMOs promote themselves as one-stop-shop companies. The one-stop-shop service model is where a CRO handles everything from API to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities to address specific problem statements.

Furthermore, increasing undertaking of strategic initiatives by key players is also expected to drive U.S. oral solid dosage (OSD) contract manufacturing market growth. For instance, in January 2023, Catalent and Ethicann collaborated to develop Ethicann's clinical drug pipeline using Catalent's orally disintegrating tablet (ODT) technology 'Zydis'. In another instance, in March 2023, Lonza announced that its new clinical and commercial drug product manufacturing line at its Visp site had become fully operational. The expansion is expected to strengthen the company's Drug Product Services (DPS) offering.

U.S. Oral Solid Dosage Contract Manufacturing Market Report Highlights:

  • Based on product type, the tablets segment captured the highest market share in 2022.This is attributed to their widespread use, ease of manufacturing, and strong patient acceptance rate
  • The capsule segment is expected to show significant market growth in the coming years. Multiple pharmacological ingredients with various release characteristics can be combined in capsules, thus driving their demand
  • Based on the mechanism, the controlled release segment dominated the market in 2022. The controlled release mechanism offers multiple advantages, such as improved efficacy and safety, reduced dosage frequency, and steady blood levels
  • Based on the end-user, the large companies segment dominated the market in 2022. Contract manufacturers generally have the capacity to scale production up or down based on requirement fluctuation. This flexibility can be advantageous for large pharma companies that experience varying levels of demand for their OSD products
  • Medium- and small-sized companies are expected to advance at a significant growth rate in the coming years. Financial resources are frequently limited for small- and medium-sized companies. Their own manufacturing facilities might be too expensive to build and operate. They can gain cutting-edge production capabilities through contract manufacturing without making a large initial investment

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Regional Scope
    • 1.1.2 Estimates And Forecast Timeline.
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
  • 1.4 Information/data Analysis
    • 1.4.1 Information Analysis
  • 1.5 Market Formulation & Visualization
  • 1.6 Data Validation & Publishing
  • 1.7 Market Definitions/scope
  • 1.8 Model Details
    • 1.8.1 Approach 1: Parent Market Analysis
    • 1.8.2 Approach 2: Service/ Commodity Flow Analysis
    • 1.8.3 Approach 3: Value-chain-based Sizing & Forecasting
    • 1.8.4 Approach 4: Qfd Model Sizing & Forecasting
  • 1.9 Market Formulation & Validation
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Primary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. Oral Solid Dosage Contract Manufacturing Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 U.S. Oral Solid Dosage Contract Manufacturing Dynamics
  • 3.3 Market Dynamics
    • 3.3.1 Market Driver Impact Analysis
    • 3.3.2 Market Restraint Analysis
  • 3.4 U.S. Oral Solid Dosage Contract Manufacturing Market: Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 PESTEL Analysis
  • 3.5 COVID-19 Impact
    • 3.5.1 Activities by Market Players
    • 3.5.2 Long-Term Changes in The Pharmaceutical Contract Manufacturing Market
  • 3.6 Analysis Pertaining to Oral Solid Dosage Packaging Types in the U.S. by Blisters vs. Bottles (Volume % Share, 2022)
    • 3.6.1 Blister Packaging
    • 3.6.2 Bottle Packaging
    • 3.6.3 Types of Blister Packaging
      • 3.6.3.1 Blister Packaging
  • 3.7 Regulatory Landscape
    • 3.7.1 U.S.
    • 3.7.2 Europe
    • 3.7.3 Rest Of The World

Chapter 4 U.S. Oral Solid Dosage Contract Manufacturing Market: Product Type Analysis

  • 4.1 U.S. Oral Solid Dosage Contract Manufacturing Market by Product Type Segment: Key Takeaways
  • 4.2 U.S. Oral Solid Dosage Contract Manufacturing Market: Product Type Movement Analysis
  • 4.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by Product Type (USD Million)
    • 4.3.1 Tablets
      • 4.3.1.1 Tablets Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.2 Capsules
      • 4.3.2.1 Capsules Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.3 Powders
      • 4.3.3.1 Powders Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.4 Granules
      • 4.3.4.1 Granules Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 4.3.5 Others
      • 4.3.5.1 Others Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 5 U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Analysis

  • 5.1 U.S. Oral Solid Dosage Contract Manufacturing Market by Mechanism Segment: Key Takeaways
  • 5.2 U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Movement Analysis
  • 5.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by Mechanism (USD Million)
    • 5.3.1 Immediate Release
      • 5.3.1.1 Immediate Release Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 5.3.2 Delayed Release
      • 5.3.2.1 Delayed Release Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 5.3.3 Controlled Release
      • 5.3.3.1 Controlled Release Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 6 U.S. Oral Solid Dosage Contract Manufacturing Market: End-user Analysis

  • 6.1 U.S. Oral Solid Dosage Contract Manufacturing Market by End-user Segment: Key Takeaways
  • 6.2 U.S. Oral Solid Dosage Contract Manufacturing Market: End-user Movement Analysis
  • 6.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by End User (USD Million)
    • 6.3.1 Large-Size Companies
      • 6.3.1.1 Large-Size Companies Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 6.3.2 Medium & Small-Size Companies
      • 6.3.2.1 Medium & Small Size Companies Contract Manufacturing Market, 2018 - 2030 (USD Million)
    • 6.3.3 Others
      • 6.3.3.1 Others Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 7 Country Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 7.1 U.S.
    • 7.1.1 Key Country Dynamics
    • 7.1.2 Competitive Scenario
      • 7.1.2.1 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Service Heat Map Analysis
  • 8.3 U.S. Oral Solid Dosage Contract Manufacturing Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Catalent, Inc.
      • 8.4.1.1 Participants' Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product/Service Benchmarking
      • 8.4.1.4 Strategy Initiatives
    • 8.4.2 Lonza
      • 8.4.2.1 Participants' Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product/Service Benchmarking
      • 8.4.2.4 Strategy Initiatives
    • 8.4.3 AbbVie Inc.
      • 8.4.3.1 Participants' Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product/Service Benchmarking
      • 8.4.3.4 Strategy Initiatives
    • 8.4.4 Aenova Group
      • 8.4.4.1 Participants' Overview
      • 8.4.4.2 Financial Performance
      • 8.4.4.3 Product/Service Benchmarking
      • 8.4.4.4 Strategy Initiatives
    • 8.4.5 Adare Pharma Solutions
    • 8.4.6 Boehringer Ingelheim International GmbH
    • 8.4.7 Jubilant Pharmova Limited
    • 8.4.8 Patheon Pharma Services
    • 8.4.9 Recipharm AB.
    • 8.4.10 Corden Pharma International
    • 8.4.11 Siegfried Holding AG

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Oral Solid Dosage Contract Manufacturing Market by Product Type, 2018 - 2030 (USD Million)
  • Table 4 U.S. Oral Solid Dosage Contract Manufacturing Market by Mechanism, 2018 - 2030 (USD Million)
  • Table 5 U.S. Oral Solid Dosage Contract Manufacturing Market by End User, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. oral solid dosage contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation and Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 Parent market analysis
  • Fig. 9 Service/Commodity Flow Analysis
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD model sizing & forecasting
  • Fig. 12 Market formulation & validation
  • Fig. 13 Market snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Segment snapshot
  • Fig. 16 Competitive landscape snapshot
  • Fig. 17 Parent market outlook, 2022 (USD Million)
  • Fig. 18 Ancillary market outlook, 2022 (USD Million)
  • Fig. 19 U.S. oral solid dosage contract manufacturing market dynamics
  • Fig. 20 Biosimilar approval in the U.S. and EU per year (2016 - 2021)
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 U.S. oral solid dosage contract manufacturing market: PESTEL analysis
  • Fig. 23 Oral solid dosage packaging types in the U.S., 2022 (volume percentage share %)
  • Fig. 24 Oral solid dosage blister packaging types in the U.S., 2022 (volume percentage share %)
  • Fig. 25 Regulatory Landscape
  • Fig. 26 U.S. oral solid dosage contract manufacturing market: Product type outlook and key takeaways
  • Fig. 27 U.S. oral solid dosage contract manufacturing market: Product type movement analysis
  • Fig. 28 U.S. tablets contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 U. S. capsules contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 U. S. powders contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. granules contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 U. S. others contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. oral solid dosage contract manufacturing market: mechanism outlook and key takeaways
  • Fig. 34 U.S. oral solid dosage contract manufacturing market: mechanism movement analysis
  • Fig. 35 U.S. immediate release contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. delayed release contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. controlled release contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. oral solid dosage contract manufacturing market: end-user outlook and key takeaways
  • Fig. 39 U.S. oral solid dosage contract manufacturing market: End-user movement analysis
  • Fig. 40 Large-Size Companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Medium & small size companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 U.S. oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key company categorization
  • Fig. 46 Service heat map analysis
  • Fig. 47 U.S. oral solid dosage contract manufacturing market share analysis, 2022